• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

This product is currently not available for purchase.


Octopus Titan VCT 3 PLC Fund Report Product Image

Octopus Titan VCT 3 PLC Fund Report

  • ID: 1217519
  • March 2015
  • 3 pages
  • Morningstar

Morningstar Stock Analyst Reports

At Morningstar, we evaluate stocks as pieces of a business, not as pieces of paper. We think that purchasing shares of superior businesses at discounts to their intrinsic value and allowing them to compound their value over long periods of time is the surest way to create wealth in the stock market.

Report Outline:


We rate stocks 1 through 5 stars, with 5 the best and 1 the worst. Our star rating is based on our analyst's estimate of how much a company's business is worth per share. Our analysts arrive at this "fair value estimate" by forecasting how much excess cash--or "free cash flow"--the firm will generate in the future, and then adjusting the total for timing and risk. Cash generated next year is worth more than cash generated several years down the road, and cash from a stable and consistently profitable business is worth more than cash from a cyclical or unsteady business.

Stocks trading at meaningful discounts to our fair value estimates will receive high star ratings. For high-quality businesses, we require a smaller discount than for mediocre ones, for a simple reason: We have more confidence in our READ MORE >

Note: Product cover images may vary from those shown

Economic Moat Rating
Discounted Cash Flow
Discount Rate
Fair Value
Margin of Safety
Consider Buying/Selling
Stewardship Grades

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.